BioSpace

OCTOBER 20, 2022

Kite Pharma entered into a global licensing deal with Refuge Biotechnologies to leverage the latter's propriety gene expression plaform and develop potential blood cancer therapies.

Gene Expression 61

Gene Expression Licensing Licensing Gene 61

Pharmaceutical Technology

NOVEMBER 28, 2022

C4X Discovery (C4XD) and AstraZeneca have entered an exclusive global licensing agreement worth up to $402m to develop oral therapy to treat inflammatory and respiratory ailments. A key natural regulator, NRF2 controls antioxidant genes’ expression.

Development 264

Development Gene Expression Licensing Licensing 264

pharmaphorum

AUGUST 2, 2021

Ipsen’s new chief executive David Loew pledged to ramp up spending on the company’s pipeline when he took the helm last year, and a flurry of licensing deals in the last few weeks shows that push is starting to gather momentum. Last December, Ipsen said it planned to spend $3.6

Gene Expression 105

Gene Expression Gene Licensing Licensing 105

XTalks

JUNE 17, 2022

Olumiant is a Janus kinase (JAK) inhibitor that was first discovered by Incyte and then licensed to Eli Lilly. It blocks the activity of JAK1 and JAK2 to interfere with the JAK-STAT signaling pathway to dampen the production of inflammatory cytokines through the modulation of gene expression.

FDA Approval 97

FDA Approval Gene Expression Cosmetics Trials 97

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China.

Licensing 52

Licensing Licensing Marketing Gene Expression 52

pharmaphorum

JANUARY 10, 2023

Astellas has licensed rights to a drug developed by Selecta Biosciences that could make more patients eligible for treatment with its gene therapy for inherited neuromuscular disorder Pompe disease. The post Astellas licenses companion drug for Pompe gene therapy appeared first on.

Gene Therapy 119

Gene Therapy Gene Licensing Licensing 119

The Pharma Data

NOVEMBER 9, 2020

Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. EMJ Allergy Immunol. 2018; 3: 60-9. 14 Peters MC, Mekonnen ZK, Yuan S, et al. J Allergy Clin Immunol. 15 Fahy JV.

Trials 52

Trials Production Sales Manufacturing 52